Acceptability of Depo-subQ Provera 104 in Uniject vs. Intramuscular Depo-Provera Among HIV+ Women & Providers, Uganda

Completed 356 enrolled Johns Hopkins Bloomberg School of Public Health Bill and Melinda Gates Foundation · collab Rakai Health Sciences Program · collab Society of Family Planning · collab

RandomizedCrossoverOpen-label

Summary

The purpose of this study is to assess acceptability and side effects of a low-dose injectable contraceptive formulation which is delivered under the skin (subcutaneously), as compared with injectable contraception delivered into the muscle (intramuscularly) among adult HIV-positive women who attend mobile clinics for HIV care and wish to use injectable contraception. The investigators will also assess experiences experiences delivering these two types of injections among health care providers working within the HIV care clinics.

Timeline

Start: 2012-04
Primary completion: 2013-03
Completion: 2013-03

Publications

Results Polis CB, Nakigozi GF, Nakawooya H, Mondo G, Makumbi F, Gray RH; Members of the Rakai Health Sciences Program Sayana Press study team. Preference for Sayana(R) Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial. Contraception. 2014 May;89(5):385-95. doi: 10.1016/j.contraception.2013.11.008. Epub 2013 Nov 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	medroxyprogesterone acetate	Other / unclassified	—	Subcutaneous

Indications

No indication recorded.